This Article Full Text Full Text (PDF) All Versions of this Article: 145/5/2148    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, F.-S. Articles by Yang, K. D. Search for Related Content PubMed PubMed Citation Articles by Wang, F.-S. Articles by Yang, K. D.

Nitric Oxide Donor Increases Osteoprotegerin Production and Osteoclastogenesis Inhibitory Activity in Bone Marrow Stromal Cells from Ovariectomized Rats

Departments of Medical Research (F.-S.W., Y.-T.H., H.-C.H., Y.-C.S., K.D.Y.) and Orthopedic Surgery (C.-J.W.), Chang Gung Memorial Hospital; Department of Orthopedic Surgery, Chang Gung University (Y.-J.C.); and Fooyin University (P.-R.C.), Ta-Liau, Kaohsiung 833, Taiwan

Address all correspondence and requests for reprints to: Dr. Kuender D. Yang, Department of Medical Research, Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niao-Sung, Kaohsiung 833, Taiwan. E-mail: wangfs{at}ms33.hinet.net.

Nitric oxide (NO) has emerged as a potent regulator useful in alleviating estrogen deficiency bone loss. Osteoprotegerin (OPG) and receptor activator of nuclear factor-B ligand (RANKL) play important roles in regulating osteoclastogenesis. Although recent studies have reported NO donor attenuation of bone loss, the effect of NO donor on OPG and RANKL expression of osteogenic stromal cells and bone microenvironment in ovariectomized rats is not fully understood. Here, we showed that optimal NO donor treatment [2,2'-(hydroxynitrosohydrazino)bis-ethanamine; 15 µM] increased OPG, but not RANKL, levels in bone marrow stromal cells from ovariectomized rats. NO donor augmentation of OPG synthesis was transcriptionally mediated. The stimulatory action of NO donor on OPG expression appeared to be regulated by tyrosine kinase-dependent activation of Cbfa1/Runx2 binding to the OPG promoter, because cell cultures pretreated with tyrosine kinase inhibitor (herbimycin A), but not with protein kinase A inhibitor (calphostain C) or protein kinase C inhibitor [(Rp)-cAMP] significantly reduced NO-augmented Runx2 activation and OPG levels. Conditioned medium from NO donor-treated cells inhibited macrophage-colony-stimulating factor and RANKL-induced osteoclast formation of macrophage-colony-stimulating factor-dependent bone marrow macrophages. Neutralization with anti-OPG antibodies abolished the inhibitory effect of conditioned medium on osteoclastogenesis. Immunohistochemical observation also showed that 2,2'-(hydroxynitrosohydrazino)bis-ethanamine increased OPG expression of osteochondral cells located at metaphyseal endosteum and calcified cartilage of proximal femurs in ovariectomized rats. These findings suggest that NO donor can be an alternative pharmacological strategy for regulating bone resorption.

This article has been cited by other articles:

				C. Zaragoza, E. Lopez-Rivera, C. Garcia-Rama, M. Saura, A. Martinez-Ruiz, T. R. Lizarbe, F. Martin-de-Lara, and S. Lamas Cbfa-1 mediates nitric oxide regulation of MMP-13 in osteoblasts. J. Cell Sci., May 1, 2006; 119(Pt 9): 1896 - 1902. [Abstract] [Full Text] [PDF]

				F.-S. Wang, C.-L. Lin, Y.-J. Chen, C.-J. Wang, K. D. Yang, Y.-T. Huang, Y.-C. Sun, and H.-C. Huang Secreted Frizzled-Related Protein 1 Modulates Glucocorticoid Attenuation of Osteogenic Activities and Bone Mass Endocrinology, May 1, 2005; 146(5): 2415 - 2423. [Abstract] [Full Text] [PDF]